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Immunosilencing peptides by 
stereochemical inversion and 
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Peptides are experiencing a new era in medical research, finding applications ranging from therapeutics 
to vaccines. In spite of the promising properties of peptide pharmaceuticals, their development 
continues to be hindered by three weaknesses intrinsic to their structure, namely protease sensitivity, 
clearance through the kidneys, and immune system activation. Here we report on two retro-D-peptides 
(H2N-hrpyiah-CONH2 and H2N-pwvpswmpprht-CONH2), which are protease-resistant and retain the 
original BBB shuttle activity of the parent peptide but are much less immunogenic than the parent 
peptide. Hence, we envisage that retro-D-peptides, which display a similar topological arrangement 
as their parent peptides, will expand drug design and help to overcome factors that lead to the failure 
of peptide pharmaceuticals in pre- and clinical trials. Furthermore, we reveal requirements to avoid or 
elicit specific humoral responses to therapeutic peptides, which might have a strong impact in both 
vaccine design and peptide therapeutic agents.
During the last three decades, peptides have become privileged therapeutics1 and are now used in a broad range of 
applications. The relevant presence of these molecules in nature and accessible synthesis through well-established 
solid-phase peptide synthesis (SPPS)2 has facilitated their study and applicability in the pharma industry3. 
Compared to therapeutics developed by classical medicinal chemistry (low molecular weight organic molecules), 
peptides display a better solubility profile, although this depends on the sequence4. While the abundance of pep-
tides in nature is advantageous from the perspective of toxicity, two principal drawbacks are intrinsic to their 
structure, namely protease degradation driven by proteolytic enzymes and eventual risk of immunogenicity1. In 
addition, this class of therapeutics displays a short plasma half-life as a result of kidney clearance. Nevertheless, 
several approaches have partially resolved these issues. Recognition by proteases, and thus peptide degradation, 
can be avoided by using peptide derivatives like D-, β-5 or non-natural amino acid peptides, as well as other 
classes of peptidomimetics6. Furthermore, PEGylation7 and other methodologies8 can extend the plasma half-life 
of peptides by increasing their molecular weight (more precisely, their hydrodynamic radius).
The immunogenicity of peptides (as the native ligands of MHC class I/II) have been studied extensively9. 
While vaccine development requires activation of the immune response10, other therapeutic treatments require 
not to elicit such type of response. Few approaches have reported effective reduction of immune system recog-
nition/response. PEGylation7 is probably the most widely used method of choice to reduce immunogenicity, 
although adverse immunological effects, i.e. humoral responses, have been reported11.
Retro-D-peptides (containing retro-inverso- and retro-enantio-isomers of a parent peptide)a are peptides 
derived from a parent peptide, made by L-amino acids, in which the sequence is reversed and made by D-amino 
acids. This rearrangement combines the properties of D-peptides, namely protease-resistance, and with the 
reversed amino acid sequence leads to an imperfect topology overlapping with that of the parent peptide but 
achieve good mimicry for short sequences12,13.
We have applied this previously described strategy to a family of peptide BBB shuttles (H2N-HAIYPRH-CONH2 
and H2N-THRPPMWSPVWP-CONH214, namely HAI and THR peptides, respectively). BBB shuttles are molecular 
entities of diverse origin, e.g. synthetic or natural peptides, which have the capacity to cross the blood-brain bar-
rier (BBB) and, when covalently conjugated to drugs unable to cross the BBB unaided, can deliver them into the 
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central nervous system (CNS)15. Those that cross through receptor-mediated transcytosis are also included in 
the term ‘molecular Trojan horses’16,17. Although only a few clinical trials on BBB shuttles have been reported18,19, 
a huge number of these molecules effectively achieve their aim20,21. While parent versions of both HAI and THR 
displayed efficient BBB permeability in several studies, our laboratory demonstrated the BBB shuttle capability and 
protease-resistance of retro-D-THR21 and retro-D-HAI.
Here we conducted immunogenicity studies for several peptide therapeutic candidates–two versions of HAI 
and THR peptides (Fig. 1), namely the parent and the respective retro-D-peptide.
Results
Validation of the retro-D-approach for HAI and THR – A structural perspective. The structural 
conformational arrangements of parent peptides and their respective retro-D-versions were studied by circu-
lar dichroism (CD) (Fig. 2b) and nuclear magnetic resonance (NMR) spectroscopy (Fig. 2a). While the coarse 
grain analysis by CD is consistent with similar conformational arrangements but not topologically exact, NMR 
adds further precision and shows how these peptides (both for HAI/retro-D-HAI and THR/retro-D-THR pairs) 
comprise several sets of thermodynamically stable conformational arrangements (see NMR data in Supporting 
Information; analysis of NMR conformationally sensitive parameters such as chemical shift deviations (CSD) 
from random coil (RC)22, coupling constants, NH temperature coefficients and NOE pattern reveal analogous 
results for the L-peptides and their retro-D-versions, thereby suggesting that they have similar conformational 
preferences). These results were contrasted by replica exchange molecular dynamics (REMD; Fig. 2c) and the 
overlapping of the two isomers was further analyzed. REMD allowed us to determine how these peptides are 
topologically disposed (see Computational Analysis in Supporting Information). Our results show that the parent 
and the retro-D-version of the same peptide can adopt a similar three-dimensional arrangement (Fig. 2c–e), in 
agreement with CD and NMR data.
Study of humoral responses elicited by peptides made by L-amino acids and their respec-
tive retro-D-versions – Implications in therapy. To date, several studies have used D-peptides as 
tools for vaccine development. In these cases the peptides have been conjugated to large supramolecular enti-
ties, e.g. KLH and small unilamelar liposomes containing monophosphoryl lipid A23,24. Nevertheless, the use of 
retro-D-peptides as therapeutics was controversial twenty years ago25,26. Thus, to shed light on the immunogenic-
ity of D-peptides and add further value to these compounds, we evaluated the immunological responses activated 
by retro-D-THR and retro-D-HAI peptides and compared them to that of their parent peptides. For this purpose, 
peptides (not conjugated) were i.p. administered to mice, and antibody titration was used as parameter to evaluate 
immunological (humoral) response by ELISA.
Unconjugated L-versions of both peptides displayed a moderate immunogenicity response (Fig. 3a). Antibody 
titration of the first bleed showed a slightly higher signal for both peptides compared to the last bleeding. This sig-
nal was probably induced by the transition from IgM to IgG production in B cells. Thus, antibody titration decay 
is caused by a decrease in number, which is compensated by an increase in affinity and selectivity. In contrast, in 
the case of retro-D-peptides almost no signal was detected for specific antibodies (Fig. 3b). Thus, retro-D-versions 
appear to be much less immunogenic than their corresponding parent peptides.
Nevertheless, in order to discard the possibility that antibody recognition was dependent on the terminus 
exposed in these cases (since retro-D-versions have them inverted and are immobilized in the ELISA plate using 
the other terminus – see Fig. 1), we tested the serum of mice immunized against retro-D-peptides by attaching 
these peptides to the other terminus on the ELISA plate (Fig. 3c and Supplementary Fig. 1). In this regard, we 
evaluated the response of antibodies to the same peptide sequence but exposing the other terminus: the inversed 
order in retro-D-peptides (comparing with parent peptides) was corrected by displaying the opposite terminus. 
As an example, the HAI peptide attached to BSA (and subsequently to the plate) by the N-terminus displayed 
the sequence H2NOC-H ← R ← P ← Y ← […]-BSA-plate, and the peptide retro-D-HAI exposing the N-terminus 
showed H2N-h → r → p → y → […]-BSA-plate (see header of Fig. 3); compare Fig. 3a and c, and see Fig. 1 and 
Figure 1. Peptide sequences of HAI, THR and the respective retro-D-versions.
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Supplementary Fig. 6b. Similar results were obtained as when retro-D-peptides exposed the C-terminus (Fig. 3c), 
thereby confirming our hypothesis (antibody reactivity does not depend on the peptide termini used to immobi-
lize them in the ELISA plate).
To the best of our knowledge, in all those immunological responses reported in the literature for either a 
retro-D-peptide or D-peptide (especially concerning vaccines), the parent one was derived from an existing 
sequence or even an immunodominant region of a viral protein23,24. Thus, these D- or retro-D-versions could 
have generated a rapid and huge immune response when administered to animals (e.g. serum IgG and other 
neutralizing factors against adeno-associated virus are highly prevalent in the healthy population27). In addition, 
a report describing D-proteins as entities exerting low immunogenicity was published 20 years ago28. We there-
fore hypothesized that retro-D-peptides with a parent sequence not related to any existing protein would not be 
immunogenic per se. To exclude this possibility in our study, we used a sequence similarity search tool (NCBI 
Figure 2. Structural analysis of the four peptides: (a) histograms showing the 1Hα, 13Cα and 13Cβ chemical 
shift deviations (CSD) from random coil (RC) of the major species (of HAI (left) and THR (right), and their 
respective retro-D-versions, aligned by amino acid type), (b) the circular dichroism (CD) spectra, (c) the cross-
RMSD derived from the comparison of the whole REMD structure sets of parent and retro-D-version peptides, 
and the three-dimensional superposition of one pairing obtained from the cross-RMSD matrix of (d) HAI and 
retro-D-HAI, and of (e) THR and retro-D-THR.
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BLAST) to identify analogies between the parent peptides used and the whole data set of known peptide and 
protein sequences. No positive result was obtained, as previously described14.
Although, as shown above, retro-D-HAI and retro-D-THR are not immunogenic per se, we hypothesize that 
they could elicit an immunological response when conjugated to an immunogenic molecule. Thus, we conjugated 
Figure 3. Titration of humoral response in mice by ELISA: (header) scheme of mice immunizations (shown 
with retro-D-HAI), ELISA evaluation of humoral response with peptide-BSA conjugates (HAI and retro-D-HAI 
shown), and the legend; (a) serum anti-parent peptides (HAI, THR), serum anti-retro-D-versions evaluated 
either with (b) C- or (c) N-terminus-exposed peptides. Initial consecutive significant differences between S0 
with S1 or S2 are labeled by asterisk/s (no asterisk, no significant differences in the whole dilution interval).
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these peptides to KLH and s.c. injected into rabbits. After the immunization, sera were tested by ELISA to iden-
tify antibodies displaying specific-peptide response. A strong increase in humoral response (see Supplementary 
Fig. 7) to these peptides was observed when compared to when they were used as unconjugated immunogens 
(Fig. 3b). The peptide-specific antibodies generated for both retro-D-peptides seems to be an immunoresponse 
facilitated by the anchoring molecule (KHL in this case). Hence, in order to be able to use this class of peptide 
(retro-D) for vaccine development, they should be coupled to other immunogenic structures to facilitate recogni-
tion by the immune system. However, if these peptides are to have applications as other types of therapeutic agent 
(and an eventual immune response is undesirable), they must be used (1) as a single therapeutic, (2) attached 
directly (2a) to the therapeutic agent or (2b) to other non-immunogenic structures.
Discussion
The B cell response (antibody production) in mice immunized with D-peptides (precisely, retro-D) that were not 
coupled to any molecule was markedly lower compared to those immunized with the L-versions. We postulate 
that both versions of the peptide may eventually be recognized by a B Cell Receptor (BCR/membrane antibody); 
nevertheless, the D-version cannot be processed by peptidases and much less efficiently presented by the MCH-II 
to CD4+ T cells (TH) —the left-handed polyproline II extended conformation adopted by peptides when loaded 
in the antigen-binding groove of MCH-II is not accessible for D-peptides (thus hydrogen bonding between the 
amide bond of the peptide and the MHC-II is hindered, although binding pockets for the side chains are pre-
served). Therefore, the survival and proliferative signals to the B cells recognizing D-peptides are much lower 
compared to those that recognize L-peptides. Thus, we propose that D-peptides have two mechanisms by which 
to silence the immune system, namely protease-resistance—that hinders the processing by peptidases and thus 
their presentation by the MHC complexes in the right size29–31—and the conformational arrangement of the 
backbone, both of which are consequences of the inversed α-carbon configuration.
Since retro-D-peptides present good topological mimicry with their parent peptides, they are a simple solu-
tion for newly designed therapeutic peptides derived from diverse source of therapeutics with L-configuration, 
e.g. natural sources, phage display or computational design. Nevertheless, given the prior observations related to 
peptides composed by D-amino acids, we recommend a preliminary screening of the sequences of interest to test 
their prevalence and type of sources in nature in order to avoid eventual immune responses in advanced trials. 
In addition, we envisage the use of retro-D-peptides as protease-resistant variants to overcome immunological 
problems derived the intrinsic structure of drugs or vectors. As an example, viral vectors applied to gene therapy 
could be decorated with these peptides in order to allow them to escape from the immune system, either attached 
through a non-immunogenic linker or stand-alone (Supplementary Fig. 9), thereby avoiding systemic adverse 
reactions and neutralization by preexisting immunity32. Furthermore, their cell-tropism could be modulated (e.g. 
by using retro-D-versions of cell-penetrating peptides (CPP), blood-brain barrier shuttles (BBB shuttles), homing 
peptides (HP)), in order to target more effectively the diseased area and thus allowing the use of lower viral loads 
(i.e. reducing side effects and production costs).
Methods
Solid-Phase Peptide Synthesis, Cleavage and Work-Up. Peptides were manually synthesized as 
C-terminal amide on H-Rink33 amide-ChemMatrix (PCAS BioMatrix Inc.) using Fmoc/tBu strategy. N-protected 
Fmoc-amino acids (4 eq.) were activated by Cl-HOBt34 (4 eq.) with N,N′-diisopropylcarbodiimide (DIPCDI) (4 eq.). 
The extent of the coupling reaction was monitored by the appropriate colorimetric test (ninhydrin35/chloranil36  
for primary/secondary amine, respectively). The growing peptide chain was deprotected with 20% piperidine 
in DMF. Peptides were cleaved from the resin, and the side chains deprotected using TFA/TIS/H2O 95:2.5:2.5. 
After drying the cleavage residue using a nitrogen flow, three cycles of washes with cold methyl tert-butyl ether 
(MTBE), followed by centrifugation, were performed to precipitate the unprotected peptide.
Peptide Purification and Characterization. Peptides were purified by reversed-phase HPLC using a symme-
try C18 column (150 × 10 mm × 5 µm, 100 Å, Waters); solvents: H2O (0.1% TFA) and CH3CN (0.1% TFA); and flow rate 
of 3 mL/min. Purity of the peptides were assessed by analytical RP-HPLC (symmetry C18 column (150 × 4.6 mm × 5 µm, 
100 Å, Waters); solvents: H2O (0.045% TFA) and CH3CN (0.036% TFA); flow rate of 1 mL/min) (Supplementary Fig. 2) 
and the identity was confirmed by MALDI-TOF MS (4700 MALDI-TOF spectrometer (PE Applied Biosystems), using 
an ACH matrix) and HRMS (Synapt HDMS (Waters) and LTQ-FT Ultra (Thermo Scientific)) (Supplementary Table 1).
Structural Characterization of Peptides. Circular dichroism spectra (Fig. 2b) were obtained with a 
J-715 circular dichroism spectropolarimeter (Jasco). Parameters used: sensitivity (standard (100 mdeg)), λ 
start (250 nm), λ end (190 nm), data pitch (0.1 nm), scanning mode (continuous), scanning speed (10 nm/min), 
response (4 sec), band width (1.0 nm), and accumulation (3). NMR experiments were performed on a Bruker 
Avance III 600 MHz spectrometer equipped with a TCI cryoprobe. Samples were prepared by dissolving peptides 
in 50 mM NaCl, 25 mM sodium phosphate buffer, H2O/D2O 90:10, pH 7.4 at 5 mM, containing 0.02% NaN3. 
Chemical shifts were referenced to internal sodium-3-(trimethylsilyl)propanesulfonate (DSS). Water signal sup-
pression was achieved by excitation sculpting37. Residue specific assignments were obtained from 2D total cor-
related spectroscopy (TOCSY) and correlation spectroscopy (COSY) experiments, while 2D nuclear Overhauser 
effect spectroscopy (NOESY) permitted sequence specific assignments. 13C resonances were assigned from 2D 
1H-13C HSQC spectra. All experiments were performed at 298 K, except NOESY spectra, which were acquired 
at 278 K. Amide proton temperature coefficients were determined from a series of one-dimensional spectra 
acquired between 278 and 308 K (Supplementary Fig. 4, Tables 2–4). TOCSY and NOESY mixing times were 70 
and 250 ms, respectively. Relative populations of the cis/trans isomers were estimated from integration of amide 
protons in the 1D 1H-NMR spectra or alternatively, when 1H integration was precluded by signal overlap, from 
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the relative intensities of 1H-13C-HSQC crosspeaks corresponding to the Pro Cδ resonances. In those cases that 
1H integration was possible, both methods provided identical results (Supplementary Table 5 and NMR data in 
Supporting Information).
Computational Analysis of the Peptide Conformations. The preferential conformation adopted by 
each peptide system was evaluated by replica exchange molecular dynamics (REMD) simulations38. Simulations 
started from a linearly extended peptide conformation built with XLEaP program module from the AMBER14 
molecular mechanics package39. The Amber ff99SB force field, together with the reoptimized proline omega-bond 
angle parameters40, was used. The initial extended peptide structure was first subjected to minimization protocol 
consisting of 1,000 steps of steep decent method followed by 500 steps of conjugate gradient method. Optimized 
structures were gradually heated to 300 K in 200 ps. The final state was chosen as the initial structure for all the 
16 replicas. Temperatures were set in a range from 300 to 500 K41. Generalized Born model42 with an effective 
salt concentration of 0.2 M was deployed to mimic the solvation effect. Nonpolar solvation term was approx-
imately represented by surface area term43. Integral time step was set to 1 fs. Temperature was regulated using 
Berendsen thermostat44 with a coupling time constant of 1 ps. SHAKE algorithm45 was used to constrain all 
the covalent bonds involving hydrogen atoms. Swaps between replicas were attempted every 2 ps, and ∼35% 
acceptance probability was obtained. Each replica was simulated during 150 ns. Snapshots were saved every 2 ps. 
To evaluate the degree of overlap between parent peptides and their retro-D-version forms, a non-symmetric 
RMSD distance matrix was built using the ptraj module of the Amber package. To preserve the correct alignment 
between the parent peptide and their retro-D-version, distances were computed between analog amino acids (i.e, 
the N-terminal amino acid of the parent peptide corresponds to C-terminal amino acid in its retro-D-version, 
and vice versa). The resulting RMSD matrix, composed of 1,000 equally spaced snapshots of the equilibrated 
part (100 ns) of the parent peptide and of its retro-D-version, was subjected to histogram analysis (Fig. 2c). 
R software46 was used in all statistical analyses. Additionally, 2D RMSD plots (mass weighted) for the same 1,000 
equally spaced snapshots of each simulation were computed to visually determine the number of clusters vis-
ited by each peptide system during the replica exchange simulation (Supplementary Fig. 5). In order to further 
compute the similarity between the conformational space sampled by the trajectories of the parent peptide and 
retro-D-version, essential dynamics techniques47,48 (Supplementary Computation Analysis Section) were used.
Peptide Conjugation to BSA or KLH. Each peptide (1 mg) was conjugated using either 1 mg of BSA 
( ≥ 98%) or KLH (premium quality) obtained from Sigma-Aldrich. For each peptide sample, proteins were dis-
solved in 0.2 mL of MES buffer (0.1 M, pH 5) and 0.9 mg of EDC dissolved in 0.1 ml of MilliQ water was added 
(Supplementary Fig. 6b). After mixing for 10 min, 1 mg of the corresponding peptide dissolved in 0.55 mL of 
MES buffer was added and the mixture was left at room temperature for 3 h. Afterwards, it was filtered using 
Amicon Ultra-3K centrifugal filter devices at 5,000 rpm for 30 min, the residue was washed with MilliQ water 
and filtered again. Finally, this residue was dissolved in MilliQ water and freeze-dried in a vial for lyophilization. 
The lyophilized products were the corresponding conjugates. Peptide-BSA conjugates were identified through 
an UltrafleXtreme MALDI-TOF mass spectrometer (Bruker Daltonics), using a 2,6,-dihydroxyacetophenone 
(DHAP) matrix (Supplementary Fig. 6a).
Mouse Immunization, Bleedings, and Serum Analysis by ELISA. Four groups of four BALB/c mice 
were treated with either one of the parent peptides or their retro-D-version. Each mouse received seven doses i.p. 
of 50 μg of peptide. Complete Freund’s49 adjuvant (CFA) was administered in the first dose, incomplete Freund’s 
adjuvant (IFA) in the subsequent five booster injections, and PBS in the last one. Bleedings for the titration 
of specific antibody production were performed before the first dose (time zero bleeding) and five days after 
the fourth and last dose (Supplementary Scheme 1). The peptide-specific humoral response was quantified by 
ELISA. MaxiSorp plates (Nunc) were treated with 0.1 mL of the corresponding peptide-BSA conjugate (1 μg) per 
well in carbonate buffer, overnight at 4 °C (Supplementary Fig. 6b). Afterwards, plates were blocked with 0.2 mL 
PBS-Tween 20 (T20) containing 2% of milk powder for 2 h a 37 °C. Each sample serum was consecutively diluted 
1/2 (starting by dilution 1:100) in PBS-T20 and incubated for 1 h at 37 °C. Incubation with a secondary antibody 
(dil. 1/5,000) anti-Mouse IgG-HRP (ref. R1253HRP; batch 26922; Acris) was left for 1 h at 37 °C. Washes (x3) 
with PBST (300 μl/well) were applied after each antibody incubation. Finally, TMB (100 μl/well) was added and 
left for 30 min, when the stop solution (100 μl, HClaq 1 N) blocked the colorimetric reaction. Plates were read at 
450 nm (Fig. 3a–c). All experiments were carried out following European guidelines (Directive 2010/63/EU, of 
22 September 2010, on the protection of animals used for scientific purposes) and approved by the animal ethics 
committee of the Universitat Autònoma de Barcelona.
Rabbit Immunization, Bleedings and Serum Analysis by ELISA. Each rabbit was immunized s.c. 
with five doses of 250 μg of the conjugate (peptide-KLH), each at different localization, altogether with CFA 
in the initial dose and IFA in the last four. Bleedings were obtained nine days after the third and the last dose 
(Supplementary Scheme 2). The peptide-specific humoral response was quantified by ELISA. Peptides were resus-
pended (8 mg/mL) in pre-adsorption buffer (23 mM NHS in DMF and 46 mM DCC in DMF, 1:1 (v/v)). MaxiSorp 
plates (Nunc) were treated with 0.1 mL of the corresponding peptide (1 μg), overnight at 4 °C. Afterwards, plates 
were blocked with 0.2 mL PBS-T20 containing 2% of milk powder for 2 h a 37 °C. Each sample serum was consec-
utively diluted 1/2 (starting by dilution 1:500) in PBS-T20 and incubated for 1 h at 37 °C. Then, an incubation with 
a secondary antibody (dil. 1/10,000) anti-Rabbit IgG- HRP (Ref. R1364HRP; batch 22489; Acris) was left for 1 h at 
37 °C. Washes (x3) with PBST (300 μl/well) were applied after each antibody incubation. Finally, TMB (100 μl/well) 
was added and left for 30 min, when the stop solution (100 μl, HClaq 1 N) blocked the colorimetric reaction. Plates 
were read at 450 nm (Supplementary Fig. 7).
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Rabbit Polyclonal Antibodies Purification and Characterization. Half the serum samples were puri-
fied through an affinity column of protein A (HiTrap Protein A HP, GE Healthcare), dialyzed against PBS × 0.1 
(membranes used: SnakeSkin® Dialysis Tubing, 10 K MWCO, 35 mm; Thermo Scientific) o/n at 4 °C with stirring 
at 100 rpm, and further characterized. Antibody purity was checked by SDS-PAGE (12% acrylamide gel; denatur-
ing conditions (sample treated for 5 min at 100 °C in loading buffer 0.2 M DTT)), while ELISA was used to test the 
specificity of the response (Supplementary Fig. 8). ELISA was performed as before purification.
Data Calculations and Statistics. Data were processed using GraphPad Prism 6.0 software. All results 
are presented as mean + SEM. Data from human serum stability assays were analyzed as non-linear one-phase 
exponential decay model for L-peptides and as standard linear model with zero slope for D-peptides. Deviations 
from a value of 100 at each dilution point were assessed using a linear model, in which group and interaction 
were included as covariates. In immune response studies, each dilution point (in ELISAs) was analyzed by a 
Mann-Whitney test to assess differences between S0 with S1 or S2. In both cases, 5% was set as a threshold for 
statistical significance.
Data availability statement. All the relevant data supporting the findings are available from the corre-
sponding author on reasonable request.
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